main-img
Back to Home » April 2021 News » GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021

GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021

April 14, 2021

BOSTON, April 14, 2021 /PRNewswire/ -- GeneLeap Bio., a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an ePoster entitled 'Hydrogel encapsulated TLR9 agonists show sustained tumor growth inhibition and prolong survival of CT26...

Source URL: https://www.prnewswire.com:443/news-releases/geneleap-presents-new-preclinical-data-for-hydrogel-encapsulated-tlr9-agonist-at-aacr-2021-301268488.html
Browse News